Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: Relation to prognosis and angiogenesis

Lung Cancer

Volumn 56, Issue 1, 2007, Pages 43-50

  Offersen, Birgitte Vrou ^a   Pfeiffer, Per ^b   Andreasen, Peter ^c   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Angiogenesis; Nonsmall cell lung carcinoma; Plasminogen activator inhibitor 1; Prognosis; Urokinase plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 33847671384     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.11.018     Document Type: Article

References (31)

1. Dano K., Andreasen P.A., Grondahl-Hansen J., Kristensen P., Nielsen L.S., and Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44 (1985) 139-266
2. Andreasen P.A., Kjoller L., Christensen L., and Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72 (1997) 1-22
3. Ellis V., Pyke C., Eriksen J., Solberg H., and Dano K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann NY Acad Sci 667 (1992) 13-31
4. Knoop A., Andreasen P.A., Andersen J.A., Hansen S., Laenkholm A.V., Simonsen S., et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 77 (1998) 932-940
5. Harbeck N., Alt U., Berger U., Kates R., Kruger A., Thomssen C., et al. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer. Int J Biol Markers 15 (2000) 79-83
6. Mignatti P., and Rifkin D.B. Plasminogen activators and angiogenesis. Curr Top Microbiol Immunol 213 (1996) 33-50
7. Mignatti P., and Rifkin D.B. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49 (1996) 117-137
8. Bajou K., Noel A., Gerard R.D., Masson V., Brunner N., Holst-Hansen C., et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4 (1998) 923-928
9. Pedersen H., Grondahl-Hansen J., Francis D., Osterlind K., Hansen H.H., Dano K., et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54 (1994) 120-123
10. Pedersen H., Brunner N., Francis D., Osterlind K., Ronne E., Hansen H.H., et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54 (1994) 4671-4675
11. Offersen B.V., Pfeiffer P., Hamilton-Dutoit S., and Overgaard J. Patterns of angiogenesis in nonsmall-cell lung carcinoma. Cancer 91 (2001) 1500-1509
12. UICC TNM, Classification of malignant tumours, 5th ed.; 1997.
13. World Health Organization. Histological typing of lung tumors. Tumori 67 (1981) 253-272
14. Pfeiffer P., Nexo E., Bentzen S.M., Clausen P.P., Andersen K., and Rose C. Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis. Br J Cancer 78 (1998) 96-99
15. Duffy M.J., Reilly D., O'Sullivan C., O'Higgins N., Fennelly J.J., and Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50 (1990) 6827-6829
16. Pappot H., Skov B.G., Pyke C., and Grondahl-Hansen J. Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry. Lung Cancer 17 (1997) 197-209
17. Salden M., Splinter T.A., Peters H.A., Look M.P., Timmermans M., van Meerbeeck J.P., et al. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol 11 (2000) 327-332
18. Pappot H., Pedersen A.N., Brunner N., and Christensen I.J. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis. Lung Cancer 51 (2006) 193-200
19. Pezzella F., Pastorino U., Tagliabue E., Andreola S., Sozzi G., Gasparin G., et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151 (1997) 1417-1423
20. Passalidou E., Trivella M., Singh N., Ferguson M., Hu J., Cesario A., et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer 86 (2002) 244-249
21. McMahon G.A., Petitclerc E., Stefansson S., Smith E., Wongn M.K., Westrick R.J., et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276 (2001) 33964-33968
22. Bajou K., Masson V., Gerard R.D., Schmitt M., Albert V., Praus M., et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152 (2001) 777-784
23. Lambert V., Munaut C., Noel A., Frankennet F., Bajou K., Gerard R.D., et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J 15 (2001) 1021-1027
24. Devy L., Blacher S., Grignet-Debrus C., Bajou K., Masson V., Gerard R.D., et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 16 (2002) 147-154
25. Isogai C., Laug W.E., Shimada H., Declerck P.J., Stins M.F., Durden D.L., et al. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res 61 (2001) 5587-5594
26. Bajou K., Maillard C., Jost M., Lijnen R.H., Gils A., Declerck P.J., et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23 (2004) 6986-6990
27. Offersen B.V., Nielsen B.S., Hoyer-Hansen G., Rank F., Hamilton-Dutoit S., Overgaard J., et al. The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol 163 (2003) 1887-1899
28. Bolon I., Gouyer V., Devouassoux M., Vandenbunder B., Wernert N., Moro D., et al. Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Am J Pathol 147 (1995) 1298-1310
29. Bolon I., Devouassoux M., Robert C., Moro D., Brambilla C., and Brambilla E. Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. Am J Pathol 150 (1997) 1619-1629
30. Robert C., Bolon I., Gazzeri S., Veyrenc S., Brambilla C., and Brambilla E. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. Clin Cancer Res 5 (1999) 2094-2102
31. Nielsen B.S., Sehested M., Duun S., Rank F., Timshel S., Rygaard J., et al. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest 81 (2001) 1485-1501